Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > J Korean Cancer Assoc > Ahead-of print articles > Article
Correspondence Reply to Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”
San-Gang Wuorcid

DOI: https://doi.org/10.4143/crt.2024.1048
Published online: November 4, 2024

Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Correspondence: San-Gang Wu, Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China
Tel: 86-5922139531 Fax: 86-59221397047 E-mail: wusg@xmu.edu.cn
• Received: October 28, 2024   • Accepted: October 31, 2024

Copyright © 2024 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 177 Views
  • 7 Download
See the letter "Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”".
Thank you for your valuable feedback on our article. There is still ongoing controversy regarding the definition of endpoints in clinical research. In our study, the primary endpoint was disease-free survival (DFS), defined as the time from the date of diagnosis to the confirmation of locoregional recurrence (LRR) or distant metastasis (DM). The secondary endpoints included locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), overall survival (OS), and safety. OS was defined as the time from the date of diagnosis to the date of death from any cause, or the last known date when the patient was alive. LRFS referred to the time from diagnosis to the date of LRR, while DMFS referred to the time from diagnosis to the date of DM [1]. The correspondence from Dr. Erkan Topkan [2] indicated that death must also be considered an event in the results concerning LRFS, DMFS, and DFS.
Several prospective studies on nasopharyngeal carcinoma have used LRFS and DMFS as study outcomes, defining them as time to LRR or DM [3-5], rather than using death as the endpoint for LRFS and DMFS, as suggested by Dr. Erkan Topkan. Additionally, the definition of DFS in current literature remains controversial. Some definitions of DFS, similar to those by Delgado and Guddati [6], describe it as the “time from randomization to disease recurrence.” However, other definitions also include “the time until the date of death or first metastasis, progression, or recurrence” [5,7], which aligns with Dr. Erkan Topkan’s definition. Therefore, an accurate definition of survival endpoints can facilitate a more precise determination of patient survival outcomes and provide an important basis for the results of clinical studies.
We have redefined DFS to include patients who experienced death as one of its endpoints, yielding similar results before (p< 0.001) and after propensity score matching (p=0.005). We would like to express our gratitude once again to Dr. Erkan Topkan for providing valuable feedback on our research.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

  • 1. Yu YF, Wu P, Zhuo R, Wu SG. Metronomic S-1 adjuvant chemotherapy improves survival in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Res Treat. 2024;56:1058–67. ArticlePubMedPMCPDF
  • 2. Topkan E, Somay E, Durankus NK, Selek U. Commentary on “metronomic S-1 adjuvant chemotherapy improves survival in patients with locoregionally advanced nasopharyngeal carcinoma.”. Cancer Res Treat. 2024 Nov 4 [Epub]. https://doi.org/10.4143/crt.2024.779ArticlePubMed
  • 3. Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2022;8:706–14. ArticlePubMedPMC
  • 4. Dai J, Zhang B, Su Y, Pan Y, Ye Z, Cai R, et al. Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2024;10:456–63. ArticlePubMed
  • 5. Wang L, Zhuang H, Xu X, Zhou J, Jiao Y. Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Front Oncol. 2023;13:1129649.ArticlePubMedPMC
  • 6. Delgado A, Guddati AK. Clinical endpoints in oncology: a primer. Am J Cancer Res. 2021;11:1121–31. PubMedPMC
  • 7. Jin YN, Qiang MY, Wang Y, Lin YJ, Jiang RW, Cao WW, et al. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis. Cancer Immunol Immunother. 2024;73:125.ArticlePubMedPMCPDF

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Reply to Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”
        Close
      • XML DownloadXML Download
      Related articles
      Reply to Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”
      Reply to Commentary on “Metronomic S-1 Adjuvant Chemotherapy Improves Survival in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma”

      Cancer Res Treat : Cancer Research and Treatment
      Close layer
      TOP